Clinical variables and probability of TFR 3 years after stopping IM
| . | N . | Rate of TFR . |
|---|---|---|
| Categorical variables | ||
| Sex | ||
| Male | 19 | 0.526 |
| Female | 21 | 0.367 |
| Sokal score | ||
| High | 4 | 0.250 |
| Intermediate | 16 | 0.365 |
| Low | 20 | 0.511 |
| Prior IFN treatment | ||
| Yes | 21 | 0.519 |
| No | 19 | 0.337 |
| Continuous variables | (below/above median) | |
| Age (y) | 40 | 0.550/0.328 |
| Duration of IM (mo) | 40 | 0.429/0.450 |
| Cumulative IM dose (g) | 40 | 0.400/0.458 |
| Duration of stable UMRD (mo) | 37 | 0.500/0.337 |
| . | N . | Rate of TFR . |
|---|---|---|
| Categorical variables | ||
| Sex | ||
| Male | 19 | 0.526 |
| Female | 21 | 0.367 |
| Sokal score | ||
| High | 4 | 0.250 |
| Intermediate | 16 | 0.365 |
| Low | 20 | 0.511 |
| Prior IFN treatment | ||
| Yes | 21 | 0.519 |
| No | 19 | 0.337 |
| Continuous variables | (below/above median) | |
| Age (y) | 40 | 0.550/0.328 |
| Duration of IM (mo) | 40 | 0.429/0.450 |
| Cumulative IM dose (g) | 40 | 0.400/0.458 |
| Duration of stable UMRD (mo) | 37 | 0.500/0.337 |
All comparisons P > .05.